1 Chun TW, Justement JS, Murray D et al. Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. AIDS 2010; 24: 2803-8.
2 Ramratnam B, Ribeiro R, He T et al. Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication. J Acquir Immune Defic Syndr 2004; 35: 33-7.
3 Strain MC, Gunthard HF, Havlir DV et al. Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence. Proc Natl Acad Sci USA 2003; 100: 4819-24.
4 Sharkey ME, Teo I, Greenough T et al. Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nat Med 2000; 6: 76-81.
5 Hankins CA, Dybul MR. The promise of pre-exposure prophylaxis with antiretroviral drugs to prevent HIV transmission: a review. Curr Opin HIV AIDS 2013; 8: 50-8.
26 Iwamoto M, Wenning LA, Nguyen BY et al. Effects of omeprazole on plasma levels of raltegravir. Clin Infect Dis 2009; 48: 489-92.
27 Kiser JJ, Bumpass JB, Meditz AL et al. Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers. Antimicrob Agents Chemother 2010; 54: 4999-5003.
28 Brainard DM, Friedman EJ, Jin B et al. Effect of low-, moderate-, and high-fat meals on raltegravir pharmacokinetics. J Clin Pharmac 2011; 51: 422-7.
29 Moss DM, Siccardi M, Back DJ et al. Predicting intestinal absorption of raltegravir using a population-based ADME simulation. J Antimicrob Chemother 2013; 68: 1627-34.
30 Anton PA, Cranston RD, Kashuba A et al. RMP-02/MTN-006: a phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate. AIDS Res Hum Retroviruses 2012; 28: 1412-21.